Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Less surgery may be just as good for Low-Risk thyroid cancer

NCT ID NCT05604963

Disease control Sponsor: University College, London Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two surgical options for people with low-risk differentiated thyroid cancer: removing only part of the thyroid (hemithyroidectomy) or the entire gland (total thyroidectomy). The goal is to see if the less extensive surgery is as effective at preventing cancer recurrence while causing fewer side effects. About 456 participants will be followed for up to 6 years after surgery.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
surgical procedure (hemithyroidectomy or total thyroidectomy)
What this could lead to
If successful, this could show that removing only part of the thyroid is a safe and cost-effective option for low-risk thyroid cancer, reducing complications from full removal.
What could go wrong
This is a non-inferiority trial, meaning it aims to prove that less surgery is not worse than more surgery. It may still show higher recurrence rates with partial removal, and results may not apply to higher-risk cancers.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 456 people

The number the study aims to enrol. It can still change while the study runs.

Started

Feb 2022

Expected to finish

Jul 2031

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

16 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Group 1 (HT already performed prior to diagnosis) Inclusion criteria • Aged 16 or over Papillary thyroid cancer: * pT1b-2 (≤4cm) irrespective of molecular genetic markers * R0 resection (clinically excised but microscopic R1 resected tumours at discretion of the local MDT) * cN0 or pN0, pNX \& pN1a (≤5 foci, no extranodal spread) * Confined to thyroid or minimal extrathyroidal extension * No higher risk histological variants on morphology (small foci allowed at the discretion of the local MDT) * No angioinvasion NB. PTC is still eligible where microscopic invasion of endothelial lined small capillary vascular spaces and lymphatic channels are present. It becomes ineligible in the rare instances when there is definite invasion of a larger vascular structure such as a vein with smooth muscle in its wall. * Encapsulated FVPTC with capsular invasion only * Micro-PTC (≤1cm) * multifocal * unifocal with pN1a (≤5 foci; no extranodal spread) Follicular thyroid cancer (FTC), including oncocytic or Hürthle cell carcinoma: * pT1b-2 (≤4cm) irrespective of molecular genetic markers \- Minimally invasive, with capsular invasion +/- minimal (≤4 foci) vascular invasion (the latter is now called encapsulated angioinvasive and is at the discretion of the MDT) * Confined to thyroid or minimal extrathyroidal extension Exclusion criteria * \>4cm * unifocal pT1a (≤1cm) PTC or FTC (unless pN1a as above) * NIFTP (non-invasive follicular thyroid neoplasm with papillary-like nuclear features) * Anaplastic, poorly differentiated or medullary thyroid carcinoma * R2 * gross extrathyroidal extension * pT4 or macroscopic tumour invasion of loco-regional tissues or structures * pN1a with \>5 foci or extranodal spread * pN1b * M1 * Aggressive PTC with any of the following features: * Widely invasive * Poorly differentiated * Anaplastic * predominance of Tall cell, Columnar cell, Hobnail, Diffuse sclerosing and other higher risk variants * FTC, including oncocytic or Hürthle cell cancer with any of the following features: * Minimally invasive with extensive vascular invasion (now called encapsulated angioinvasive) (\>4 foci) * Widely invasive * Poorly differentiated * Anaplastic Group 2 (DTC on cytology or after core biopsy, who has not had prior thyroid surgery yet) Inclusion criteria * Aged 16 or over * 'low risk' differentiated thyroid cancer confirmed by cytology or core biopsy. * cT1b-2 irrespective of molecular genetic markers * cN0 * Contralateral lobe without suspicious nodule(s) (U2, or U3/U4 with Thy2 on FNAC) Exclusion criteria • M1

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Differentiated thyroid cancer are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

differentiated thyroid carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Differentiated thyroid cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    33 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Addenbrooke's Hospital

    RECRUITING

    Cambridge, United Kingdom

  • Colchester Hospital

    RECRUITING

    Colchester, United Kingdom

  • Derriford Hospital

    RECRUITING

    Plymouth, United Kingdom

  • Forth Valley Royal Hospital

    RECRUITING

    Falkirk, United Kingdom

  • Glan Clwyd Hospital (Betsi Cadwaladr University Health Board)

    RECRUITING

    Rhyl, United Kingdom

  • Guy's Hospital

    RECRUITING

    London, United Kingdom

  • Ipswich Hospital

    RECRUITING

    Ipswich, United Kingdom

  • Leicester Royal Infirmary

    RECRUITING

    Leicester, United Kingdom

  • Leighton Hospital

    RECRUITING

    Crewe, Cheshire, CW1 4QJ, United Kingdom

  • Lister Hospital

    RECRUITING

    London, United Kingdom

  • Liverpool University Hospitals

    RECRUITING

    Liverpool, United Kingdom

  • Luton and Dunstable University Hospital

    RECRUITING

    Luton, United Kingdom

  • Medway Maritime Hospital

    RECRUITING

    Gillingham, United Kingdom

  • Musgrove Park Hospital

    RECRUITING

    Taunton, United Kingdom

  • NHS Greater Glasgow & Clyde

    RECRUITING

    Glasgow, United Kingdom

  • NHS Lothian

    RECRUITING

    Edinburgh, United Kingdom

  • Ninewells Hospital

    RECRUITING

    Dundee, United Kingdom

  • Norfolk and Norwich University Hospital

    RECRUITING

    Norwich, United Kingdom

  • Northampton General Hospital

    RECRUITING

    Northampton, United Kingdom

  • Northwick Park Hospital

    RECRUITING

    London, United Kingdom

  • Nottingham University Hospitals NHS Trust

    NOT_YET_RECRUITING

    Nottingham, United Kingdom

  • Queen Alexandra Hospital

    RECRUITING

    Portsmouth, United Kingdom

  • Queen Elizabeth Hospital

    RECRUITING

    Birmingham, United Kingdom

  • Royal Derby Hospital

    RECRUITING

    Derby, United Kingdom

  • Royal Devon and Exeter Hospital

    RECRUITING

    Exeter, United Kingdom

  • Royal United Hospital

    NOT_YET_RECRUITING

    Bath, United Kingdom

  • Sheffield Teaching Hospitals

    RECRUITING

    Sheffield, United Kingdom

  • St George's Hospital

    RECRUITING

    London, United Kingdom

  • The Royal Marsden Hospitals

    RECRUITING

    London, United Kingdom

  • University College London Hospital

    NOT_YET_RECRUITING

    London, United Kingdom

  • University Hospital of Wales

    RECRUITING

    Cardiff, United Kingdom

  • University Hospitals Bristol and Weston NHS Foundation Trust

    RECRUITING

    Bristol, United Kingdom

  • University Hospitals Dorset NHS Foundation Trust

    RECRUITING

    Poole, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.